ALGS (STOCKS)
Aligos Therapeutics, Inc. Common Stock
$6.875000
-0.125000 (-1.79%)
Prev close: $7.000000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Lawrence M. Blatt
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $67.94M
- Employees
- 70
- P/E (TTM)
- -0.96
- P/B (TTM)
- 1.37
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
10
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.14 | $-1.10 | +0.9550 | +87.21% |
|
Mar 2026 (Q1)
|
$-2.21 | $-2.27 | +0.0575 | +2.54% |
|
Dec 2025 (Q4)
|
$-1.91 | $-1.89 | -0.0210 | -1.11% |
|
Sep 2025 (Q3)
|
$-3.04 | $-1.94 | -1.1020 | -56.86% |
Financial Statements
| Revenues | $3.74M |
| Benefits Costs and Expenses | $76.49M |
| Costs And Expenses | $76.49M |
| Operating Expenses | $110.51M |
| Research and Development | $88.38M |
| Other Operating Expenses | $22.14M |
| Operating Income/Loss | -$78.99M |
| Income/Loss From Continuing Operations After Tax | -$75.96M |
| Income/Loss From Continuing Operations Before Tax | -$72.75M |
| Income Tax Expense/Benefit | $3.21M |
| Interest Income/Expense After Provision For Losses | $1.40M |
| Interest Income/Expense Operating, Net | $1.40M |
| Net Income/Loss | -$75.96M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$75.96M |
| Net Income/Loss Available To Common Stockholders, Basic | -$75.96M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$7.41 |
| Diluted Earnings Per Share | -$7.41 |
| Basic Average Shares | 20,954,559 |
| Diluted Average Shares | 20,954,559 |
| Assets | $66.33M |
| Current Assets | $62.13M |
| Noncurrent Assets | $4.20M |
| Fixed Assets | $1.33M |
| Other Non-current Assets | $2.87M |
| Liabilities | $34.44M |
| Current Liabilities | $28.34M |
| Accounts Payable | $6.43M |
| Wages | $4.74M |
| Other Current Liabilities | $17.18M |
| Noncurrent Liabilities | $6.10M |
| Equity | $31.88M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $31.88M |
| Liabilities And Equity | $66.33M |
| Net Cash Flow From Operating Activities | -$94.17M |
| Net Cash Flow From Operating Activities, Continuing | -$94.17M |
| Net Cash Flow From Investing Activities | $105.59M |
| Net Cash Flow From Investing Activities, Continuing | $105.59M |
| Net Cash Flow From Financing Activities | $228.00K |
| Net Cash Flow From Financing Activities, Continuing | $228.00K |
| Net Cash Flow | $11.65M |
| Net Cash Flow, Continuing | $11.65M |
| Comprehensive Income/Loss | -$75.95M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$75.95M |
| Other Comprehensive Income/Loss | -$75.95M |
| Other Comprehensive Income/Loss Attributable To Parent | $17.00K |